Combination Chemotherapy in Treating Children With Neuroblastoma

Key facts

Sponsor

Children's Oncology Group

Principal Investigator

David L. Baker, MD, MBBS, FRACP, FRCPA

Princess Margaret Hospital for Children

Intervention

filgrastim(biological)

Enrollment

573 enrolled

Eligibility

20 years · All sexes

Timeline

1988 – 2011

Study locations (30)

• Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
• University of South Alabama Cancer Research Institute, Mobile, Alabama, United States
• Phoenix Children's Hospital, Phoenix, Arizona, United States
• Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Southern California Permanente Medical Group, Downey, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
• Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
• Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
• Children's Hospital Central California, Madera, California, United States
• Children's Hospital and Research Center - Oakland, Oakland, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07549321
  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients
  Renaissance Pharma Ltd.
• RECRUITINGPHASE1, PHASE2NCT06625190
  Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
  University of Florida
• RECRUITINGPHASE1NCT07172958
  Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
  Children's National Research Institute
• RECRUITINGPHASE2NCT07085338
  A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
  St. Jude Children's Research Hospital
• RECRUITINGPHASE1, PHASE2NCT07399821
  An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE1NCT06995872
  Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06814496
  Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  University of Arizona
• RECRUITINGPHASE1NCT07087002
  GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
  Stanford University

See all trials for Neuroblastoma →